Comparison of Focused ESWT by Low and High Frequency for Patients With Myofascial Pain Syndrome: a Pilot Study
试验速览
- 阶段
- 不适用
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Change from baseline NRS (numerical rating scale) at each time frame
研究概览
简要总结
To investigate the efficacy and safety according to the frequency of focused ESWT in patients with myofascial pain syndrome.
详细描述
Myofascial pain syndrome is one of the common causes of musculoskeletal pain seen in clinical practice and is characterized by the presence of trigger points associated with sensitive areas such as taut bands of skeletal muscle. It may also be accompanied by referred pain, which is pain in other parts of the body. Although the pathophysiology and etiology of myofascial pain syndrome and trigger points are still unknown, there are reports that myofascial pain is a complex form of neuromuscular dysfunction caused by motor and sensory abnormalities involving both the peripheral nervous system and the central nervous system. Recently, it has been considered as a method of treatment for myofascial pain syndrome. In addition, although pain reduction and functional improvement of focused ESWT in patients with myofascial pain syndrome have been reported, related studies are lacking on the effect of focused ESWT according to the frequency difference. The purpose of the study is to examine the efficacy and safety of focused type ESWT frequency in patients with myofascial pain syndrome.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Those diagnosed with myofascial pain syndrome according to Simon's criteria
- •Pain is 4 points or more on the Numerical Rating Scale (NRS)
排除标准
- •Pain is due to trauma, fibromyalgia and neurological disorders including neuromyopathy, myelopathy, and stroke
- •If you have received injection treatment for trigger points within the last 2 months or have had surgery on the painful area within 1 year
- •If there is a high risk of bleeding due to severe coagulopathy, etc. or if you have recently had severe bleeding (except taking antiplatelet)
- •If you have a tumor, infection, kidney failure, severe liver disease, epilepsy, skin disease, or mental retardation
结局指标
主要结局
Change from baseline NRS (numerical rating scale) at each time frame
时间窗: baseline, immediately after primary treatment, 1 day after primary treatment, 3 day after primary treatment, immediately after secondary treatment, 1 day after secondary treatment, 3 day after secondary treatment
Pain intensity (0-10, ordinal scale)
次要结局
- Number of treatment-related adverse events as assessed by CTCAE v4.0 at each time frame(immediately after primary treatment, 1 day after primary treatment, 3 day after primary treatment, immediately after secondary treatment, 1 day after secondary treatment, 3 day after secondary treatment)